TradingKey

자세한 내용은 Gilead Sciences Inc 회사

Gilead Sciences, Inc. is a biopharmaceutical company. The Company is engaged in advancing medicines to prevent and treat life-threatening diseases, including human immunodeficiency virus (HIV), viral hepatitis, COVID-19, cancer and inflammation. It is focused on discovering, developing and delivering medicines to address unmet medical needs in virology, oncology and other therapeutic areas. Its portfolio of marketed products includes Biktarvy, Genvoya, Descovy, Complera/Eviplera, Symtuza, Truvada, Stribild, Sunlenca, Epclusa, Vemlidy, Harvoni, Viread, Livdelzi, Veklury, Yescarta, Tecartus, Trodelvy, AmBisome, and Letairis. Its product candidates include Bulevirtide, Lenacapavir, Axicabtagene ciloleucel, Anitocabtagene autoleucel, Sacituzumab govitecan-hziy, and Domvanalimab and zimberelimab. Biktarvy is an oral formulation dosed once a day for the treatment of HIV-1 infection in certain patients. It operates in more than 35 countries worldwide.

회사 정보

회사 코드GILD

회사 이름Gilead Sciences Inc

상장일Jan 22, 1992

설립일1987

CEOMr. Daniel P. O'Day

직원 수17600

유형Ordinary Share

회계 연도 종료Jan 22

주소333 Lakeside Dr

도시FOSTER CITY

증권 거래소NASDAQ Global Select Consolidated

국가United States of America

우편 번호94404-1147

전화16505743000

웹사이트https://www.gilead.com/

회사 코드GILD

상장일Jan 22, 1992

설립일1987

회사 임원

이름

이름/직위

직위

주식 보유

변동

Ms. Johanna Mercier

Chief Commercial Officer

96.93K

+4.50%

Dr. Jacqueline K. Barton, Ph.D.

Independent Director

26.06K

+6.18%

Ms. Deborah H. (Deb) Telman

Executive Vice President - Corporate Affairs, General Counsel

19.90K

+1.82%

Mr. Anthony (Tony) Welters, J.D.

Lead Independent Director

11.75K

+14.82%

Ms. Kelly A. Kramer

Independent Director

1.34K

--

Dr. Dietmar P. Berger, M.D., Ph.D.

Chief Medical Officer

--

Mr. Andrew D. (Andy) Dickinson

Chief Financial Officer

--

Mr. Harish Manwani

Independent Director

--

Dr. Ted W. Love, M.D.

Independent Director

--

Mr. Javier J. Rodriguez

Independent Director

--

이름

이름/직위

직위

주식 보유

변동

Ms. Johanna Mercier

Chief Commercial Officer

96.93K

+4.50%

Dr. Jacqueline K. Barton, Ph.D.

Independent Director

26.06K

+6.18%

Ms. Deborah H. (Deb) Telman

Executive Vice President - Corporate Affairs, General Counsel

19.90K

+1.82%

Mr. Anthony (Tony) Welters, J.D.

Lead Independent Director

11.75K

+14.82%

Ms. Kelly A. Kramer

Independent Director

1.34K

--

Dr. Dietmar P. Berger, M.D., Ph.D.

Chief Medical Officer

--

수익 분석

통화: USD업데이트 시간: Sun, Apr 6

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2022Q1

FY2021

FY2020

FY2019

FY2018

FY2017

FY2016

FY2015

사업별USD

이름

수익

비율

Biktarvy

13.42B

46.69%

Descovy

2.11B

7.35%

Genvoya

1.76B

6.13%

Sofosbuvir/Velpatasvir

1.59B

5.55%

Yescarta

1.57B

5.46%

Other

8.29B

28.83%

지역별USD

이름

수익

비율

United States

19.51B

67.84%

Europe

4.35B

15.12%

Other Locations

2.91B

10.11%

사업별

지역별

사업별USD

이름

수익

비율

Biktarvy

13.42B

46.69%

Descovy

2.11B

7.35%

Genvoya

1.76B

6.13%

Sofosbuvir/Velpatasvir

1.59B

5.55%

Yescarta

1.57B

5.46%

Other

8.29B

28.83%

주주

업데이트 시간: Fri, Feb 21

주주 통계

유형

주주 통계

주주

비율

The Vanguard Group, Inc.

9.40%

Capital World Investors

5.76%

BlackRock Institutional Trust Company, N.A.

5.68%

State Street Global Advisors (US)

4.85%

Capital Research Global Investors

4.66%

Other

69.64%

주주 통계

주주

비율

The Vanguard Group, Inc.

9.40%

Capital World Investors

5.76%

BlackRock Institutional Trust Company, N.A.

5.68%

State Street Global Advisors (US)

4.85%

Capital Research Global Investors

4.66%

Other

69.64%

유형

주주

비율

Investment Advisor

42.26%

Investment Advisor/Hedge Fund

35.74%

Pension Fund

3.12%

Research Firm

3.09%

Bank and Trust

1.74%

Sovereign Wealth Fund

1.72%

Hedge Fund

1.60%

Insurance Company

0.17%

Individual Investor

0.08%

Other

10.47%

기관 주식 보유

업데이트 시간: Sun, Jan 19

보고 기간

기관 수

보유 주식

비율

변동

2025Q1

3341

1.12B

89.83%

-2.17M

2024Q4

3313

1.12B

90.13%

+4.63M

2024Q3

3207

1.10B

88.48%

-11.56M

2024Q2

3188

1.10B

88.24%

-14.37M

2024Q1

3196

1.10B

88.13%

-22.04M

2023Q4

3252

1.11B

88.75%

-8.79M

2023Q3

3190

1.10B

88.14%

-23.58M

2023Q2

3196

1.10B

88.02%

-11.22M

2023Q1

3195

1.09B

87.26%

-11.17M

2022Q4

3203

1.08B

86.64%

+1.09M

주주 활동

이름

보유 주식

비율

변동

Chg %

날짜

The Vanguard Group, Inc.

114.97M

9.22%

+203.25K

+0.18%

Dec 31, 2024

Capital World Investors

71.71M

5.75%

-4.84M

-6.33%

Dec 31, 2024

BlackRock Institutional Trust Company, N.A.

74.47M

5.97%

-1.75M

-2.30%

Dec 31, 2024

State Street Global Advisors (US)

60.38M

4.84%

+210.06K

+0.35%

Dec 31, 2024

Capital Research Global Investors

57.95M

4.65%

-3.85M

-6.24%

Dec 31, 2024

Wellington Management Company, LLP

35.66M

2.86%

+1.06M

+3.06%

Dec 31, 2024

Fidelity Management & Research Company LLC

34.64M

2.78%

+6.42M

+22.73%

Dec 31, 2024

Dodge & Cox

32.95M

2.64%

-98.02K

-0.30%

Dec 31, 2024

Geode Capital Management, L.L.C.

28.29M

2.27%

+749.05K

+2.72%

Dec 31, 2024

Invesco Capital Management (QQQ Trust)

25.78M

2.07%

+346.10K

+1.36%

Feb 28, 2025

관련 ETF

업데이트 시간: Tue, May 6

이름

비율

VanEck Biotech ETF

12%

Invesco Nasdaq Biotechnology ETF

8.24%

ProShares Ultra Nasdaq Biotechnology

7.84%

iShares Biotechnology ETF

7.01%

Global X US Cash Flow Kings 100 ETF

5.67%

Coastal Compass 100 ETF

5.45%

Invesco Pharmaceuticals ETF

5%

Invesco Biotechnology & Genome ETF

4.76%

TBG Dividend Focus ETF

4.5%

First Trust NASDAQ Pharmaceuticals ETF

4%

VanEck Biotech ETF

비율12%

Invesco Nasdaq Biotechnology ETF

비율8.24%

ProShares Ultra Nasdaq Biotechnology

비율7.84%

iShares Biotechnology ETF

비율7.01%

Global X US Cash Flow Kings 100 ETF

비율5.67%

Coastal Compass 100 ETF

비율5.45%

Invesco Pharmaceuticals ETF

비율5%

Invesco Biotechnology & Genome ETF

비율4.76%

TBG Dividend Focus ETF

비율4.5%

First Trust NASDAQ Pharmaceuticals ETF

비율4%

주식 배당금

지난 5년 동안 총 18.49B USD의 배당금이 분배되었습니다.

날짜

배당금

기준일

지급일

배당락일

Feb 11, 2025

GILD.NB Interim Cash Dividend of gross USD 0.79 paid on Mar 28, 2025 going ex on Mar 14, 2025

Mar 14, 2025

Mar 28, 2025

Mar 14, 2025

Nov 12, 2024

GILD.NB Final Cash Dividend of gross USD 0.77 paid on Dec 30, 2024 going ex on Dec 13, 2024

Dec 13, 2024

Dec 30, 2024

Dec 13, 2024

Aug 13, 2024

GILD.NB Interim Cash Dividend of gross USD 0.77 paid on Sep 27, 2024 going ex on Sep 13, 2024

Sep 13, 2024

Sep 27, 2024

Sep 13, 2024

Apr 26, 2024

GILD.NB Interim Cash Dividend of gross USD 0.77 paid on Jun 27, 2024 going ex on Jun 14, 2024

Jun 14, 2024

Jun 27, 2024

Jun 14, 2024

Feb 06, 2024

GILD.NB Interim Cash Dividend of gross USD 0.77 paid on Mar 28, 2024 going ex on Mar 14, 2024

Mar 15, 2024

Mar 28, 2024

Mar 14, 2024

Nov 08, 2023

GILD.NB Final Cash Dividend of gross USD 0.75 paid on Dec 28, 2023 going ex on Dec 14, 2023

Dec 15, 2023

Dec 28, 2023

Dec 14, 2023

Aug 07, 2023

GILD.NB Interim Cash Dividend of gross USD 0.75 paid on Sep 28, 2023 going ex on Sep 14, 2023

Sep 15, 2023

Sep 28, 2023

Sep 14, 2023

Apr 28, 2023

GILD.NB Interim Cash Dividend of gross USD 0.75 paid on Jun 29, 2023 going ex on Jun 14, 2023

Jun 15, 2023

Jun 29, 2023

Jun 14, 2023

Feb 02, 2023

GILD.NB Interim Cash Dividend of gross USD 0.75 paid on Mar 30, 2023 going ex on Mar 14, 2023

Mar 15, 2023

Mar 30, 2023

Mar 14, 2023

Oct 27, 2022

GILD.NB Final Cash Dividend of gross USD 0.73 paid on Dec 29, 2022 going ex on Dec 14, 2022

Dec 15, 2022

Dec 29, 2022

Dec 14, 2022

주식 분할

날짜

유형

비율

데이터 없음

날짜

유형

비율

데이터 없음

gild

96.910USD

gild

96.910

개요

회사